drugset / Trial / NCT05966584
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
Phase 2
Terminated
1 enrolled
Memorial Sloan Kettering Cancer Center
AstraZeneca · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib. Researchers think adding benralizumab to the standard-of-care hormone treatment and alpelisib may prevent the patient from getting a rash.
Timeline
- Start
- 2023-07-06
- Primary completion
- 2024-08-02
- Completion
- 2024-08-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benralizumab | Monoclonal antibody | 30 mg | Subcutaneous |
| Background | Alpelisib | Small molecule | — | — |
| Background | Fulvestrant | Small molecule | — | — |